Optic IconOptic Logo
|
SearchCollectionsBenchmarks

Rivaroxaban

Aliases
dabigatran, Eliquis, Lixiana, Pradaxa, rivaroxaban (2 other aliases)

83 clinical trials

1 product

9 abstracts

96 indications

Indication
Thrombosis
Indication
Venous Thromboembolism
Indication
Atrial Fibrillation
Indication
Antiphospholipid Syndrome
Indication
Systemic Lupus Erythematosus
Indication
stroke
Indication
Healthy Control Participants
Indication
Surgery
Indication
Mouth
Indication
Hemorrhage
Indication
Postoperative Complications
Indication
Oral Surgery
Indication
Anticoagulant-Related Adverse Effects
Indication
Anticoagulant-induced Bleeding
Indication
Cirrhosis
Indication
Splenectomy
Indication
Venous Thrombosis
Indication
Hypertension
Indication
portal
Indication
Cerebral Ischemia
Indication
COVID-19
Indication
SARS
Indication
Healthy
Indication
Deep Vein Thrombosis
Indication
Post-thrombotic syndrome
Indication
Leg Injury
Indication
Cerebral Vein Thrombosis
Indication
Hematopoietic and Lymphoid Cell Neoplasm
Indication
Malignant Solid Neoplasm
Indication
Metastatic Malignant Solid Neoplasm
Indication
Pulmonary Embolism
Indication
Splanchnic Vein Thrombosis
Indication
Intracranial Hemorrhage
Indication
Varicose Veins
Indication
Atherosclerosis
Indication
Stenosis
Indication
Intracerebral hemorrhage
Indication
Heart Attack
Indication
Peripartum Cardiomyopathy
Indication
Postpartum
Indication
Spinal Cord Injuries
Indication
Spinal Diseases
Indication
Aortic Valve Stenosis
Indication
Cardiovascular Diseases
Indication
Heart Diseases
Indication
Heart Valve Disease
Indication
Valve Disease
Indication
Aortic
Indication
Menstruation
Indication
Multiple Myeloma in Relapse
Indication
Multiple Myeloma
Indication
Multiple Myeloma Stage II
Indication
Multiple Myeloma Stage I
Indication
Multiple Myeloma With Failed Remission
Indication
Multiple Myeloma Stage III
Indication
Cancer
Indication
Venous thromboembolism
Indication
Acute Coronary Syndrome
Indication
Left Ventricular Thrombus
Indication
Intrahepatic Non Cirrhotic Portal Hypertension
Indication
Bleeding
Indication
Ischemic
Indication
chronic thromboembolic pulmonary hypertension
Indication
Stroke
Indication
Transient Ischemic Attack
Indication
Fragility
Indication
Embolism
Indication
Embolism and Thrombosis
Indication
Lung Diseases
Indication
Respiratory Tract Diseases
Indication
May-Thurner Syndrome
Indication
pulmonary embolism
Indication
Type 2 Diabetes
Indication
Thromboembolism
Indication
Atrial High Rate Episodes
Indication
Left Atrial Appendage Thrombosis
Indication
Venous
Indication
Complications of Catheterization
Indication
Congestive Heart Failure
Indication
ST Elevation Myocardial Infarction
Indication
Intracardiac Thrombus
Indication
End Stage Renal Failure on Dialysis
Indication
Obesity
Indication
Morbid
Indication
Radial Artery Occlusion
Indication
Blood thinners
Indication
Cerebrovascular Stroke
Indication
Anticoagulant
Indication
Matrix Metalloproteinases
Indication
Iliac Vein Thrombosis
Indication
Iliac vein obstruction
Indication
Iliac Vein Stenosis
Indication
Superficial Thrombophlebitis
Indication
Cerebrovascular Atherosclerosis
Indication
Knee Replacement
Indication
Anticoagulant therapy
Clinical trial
Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.
Status: Not yet recruiting, Estimated PCD: 2028-02-01
Clinical trial
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (BRAIN-AF)
Status: Terminated, Estimated PCD: 2024-05-18
Clinical trial
Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open-label, Phase IIb, Non-inferiority Proof of Principle Trial.
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-12-10
Clinical trial
Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy
Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
An Open-Label Study to Investigate the Effect of Selpercatinib on the Pharmacokinetics of Dabigatran in Healthy Volunteers
Status: Completed, Estimated PCD: 2021-05-17
Clinical trial
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome Phase IV Pilot Study
Status: Terminated, Estimated PCD: 2024-01-19
Abstract
A prospective cohort study on rivaroxaban in the prevention of catheter-related thrombosis in breast cancer.
Org: Department of Medical Oncology, Beijing Chaoyang District San Huan Cancer Hospital, Beijing, China, Department of Medical Oncology, Beijing Chao yang District San huan Cancer Hospital, Beijing, China, Beijing Chaoyang District San Huan Cancer Hospital, Beijing, China, Special Medical Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Clinical trial
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Status: Active (not recruiting), Estimated PCD: 2022-06-07
Clinical trial
Comparison Between Continuous Oral Anticoagulation Versus Pill-in-the-POCKET Oral AntiCoagulation Strategy Guided by Continuous Rhythm Monitoring Using Implantable Loop Recorder After Atrial Fibrillation Catheter Ablation
Status: Recruiting, Estimated PCD: 2030-12-31
Abstract
Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.
Org: Cleveland Clinic Taussig Cancer Instititute,
Clinical trial
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study
Status: Completed, Estimated PCD: 2017-11-01
Clinical trial
Anticoagulation Using Rivaroxaban on Top of Aspirin in Recent Stroke/Transient Ischemic Attack Patients With Intracranial Atherosclerotic Stenosis (AA-ICAS)
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF)
Status: Completed, Estimated PCD: 2024-05-31
Clinical trial
Prospective Study on the Impact of Different Anti-thrombotic Therapies on Subclinical Leaflet Thickening and Its Temporal Dynamics in Transcatheter Bioprosthetic Aortic Valves (NOTION-4)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients: Define CCS Study, a Prospective Randomized Crossover Clinical Trial.
Status: Recruiting, Estimated PCD: 2023-11-01
Clinical trial
Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women
Status: Completed, Estimated PCD: 2020-02-13
Clinical trial
Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)
Status: Completed, Estimated PCD: 2020-10-31
Clinical trial
OBServaToire INternational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
Status: Recruiting, Estimated PCD: 2030-04-01
Clinical trial
Efficacy of Rivaroxaban in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction: An Open Label Randomized Control Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
Status: Active (not recruiting), Estimated PCD: 2026-07-31
Clinical trial
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
Status: Recruiting, Estimated PCD: 2026-10-30
Clinical trial
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
Status: Completed, Estimated PCD: 2023-10-27
Clinical trial
Trial of New Oral Anticoagulants vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
Status: Completed, Estimated PCD: 2023-10-01
Clinical trial
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
Status: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
An Investigator-initiated, Multicenter, Phase 3, Randomized, Single-blind, Double-dummy, Parallel-group Study of Evaluate the Efficacy and Safety of Edoxaban Versus Warfarin (Vitamin K Antagonist) in Subjects With Chronic Thromboembolic Pulmonary Hypertension Taking Warfarin (Vitamin K Antagonist) at Baseline: KABUKI
Status: Completed, Estimated PCD: 2023-03-30
Clinical trial
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation: a Prospective, Multicenter, Cohort Study
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation: the ORIGAMI II Study
Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS)：A Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-07-21
Clinical trial
The efficAcy and Safety of aPixaban In REal-world Practice in Korean Frail Patients With Atrial Fibrillation: a Prospective Multicenter Non-interventional, Observational Study: ASPIRE Study
Status: Active (not recruiting), Estimated PCD: 2022-03-04
Clinical trial
Anticoagulant Treatment Patterns and Outcomes Among Non-valvular Atrial Fibrillation Patients With High Risk of Gastrointestinal Bleeding in France: a Retrospective Cohort Analysis Using SNDS Database
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation
Status: Completed, Estimated PCD: 2018-12-12
Clinical trial
Identification of Clinical and Pharmacogenetic Factors Predictive of Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation.
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Clinical trial
A Phase IV Study on Impact of Edoxaban Treatment in Italian Cancer Patients With Venous Thromboembolism (EDOI Cancer Study) During Antineoplastic Therapy
Status: Completed, Estimated PCD: 2022-03-08
Clinical trial
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET
Status: Terminated, Estimated PCD: 2022-12-31
Clinical trial
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Status: Completed, Estimated PCD: 2020-04-01
Clinical trial
Resolution of Thrombi in Left Atrial Appendage With Edoxaban
Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
Pharmacokinetics and Safety Profile of Apixaban in Patients With Peritoneal Dialysis
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
A Randomized, Multicenter, Open-Label, Control, Clinical Trial to Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-06-11
Clinical trial
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Status: Terminated, Estimated PCD: 2023-03-31
Clinical trial
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2021-02-18
Clinical trial
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
Status: Completed, Estimated PCD: 2023-10-05
Clinical trial
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.
Status: Recruiting, Estimated PCD: 2022-03-30
Clinical trial
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population at Different Cardiac Sites
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
FREEDOM COVID Anticoagulation Strategy Randomized Trial
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis (SAFE-D)
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer
Status: Terminated, Estimated PCD: 2021-09-01
Clinical trial
Rivaroxaban Compared to Warfarin for Treatment of Cerebral Venous Thrombosis: a Randomized Controlled Trial
Status: Completed, Estimated PCD: 2020-03-01
Clinical trial
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
Status: Completed, Estimated PCD: 2022-06-15
Clinical trial
VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)
Status: Active (not recruiting), Estimated PCD: 2024-12-02
Clinical trial
To Explore the Predictive Value of Infarction Volume on Hemorrhagic Transformation in Newly Diagnosed Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Comparison of Warfarin Versus Rivaroxaban in Management of Post-myocardial Infarction Left Ventricular Thrombus in a Tertiary Cardiac Center of Nepal: a Randomized Control Study.
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux
Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Status: Recruiting, Estimated PCD: 2027-03-05
Clinical trial
A Parallel Group Study in Healthy Participants to Quantitate Increases in Subclinical Gastrointestinal Blood Loss Following Administration of Aspirin Alone or in Combination With Rivaroxaban or Factor XI Inhibitors (REGN9933 or REGN7508)
Status: Not yet recruiting, Estimated PCD: 2025-04-07
Abstract
Evaluation of bleeding risk between apixaban and rivaroxaban in patients with gastrointestinal cancer.
Org: Emory University Hospital Midtown, Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Astellas Pharma, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Anticoagulation for portal vein thrombosis in patients with hepatocellular carcinoma: A retrospective observational study.
Org: Trinity Health of New England, Corewell Health System - Beaumont University Hospital, William Beaumont University Hospital,
Abstract
Apixaban versus rivaroxaban for treatment of acute deep venous thrombosis in patients with cancer.
Org: Department of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, Alara Medical Group,
Abstract
Real world data for venous thromboembolisms (VTEs) in patients with active cancer: Thromboprophylaxis pooled analysis from GMaT and ACT4CAT studies.
Org: Hellenic Society of Medical Oncology, HeSMO,
Abstract
Use of direct oral anticoagulants (DOACs) in oncology: A phase IV study on impact of edoxaban treatment in Italian patients with cancer with venous thromboembolism during antineoplastic therapy (EDOI trial, GOIRC 05-2018).
Org: IRCCS AUSL Reggio Emilia, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, University of Turin at Ordine Mauriziano Hospital, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Anticoagulation prescribing practices in high-risk, under-represented patients with malignancy and venous thromboembolism (VTE).
Org: Temple University Hospital, Philadelphia, PA,
Abstract
Transformation of tissue-resident, very small embryonic-like stem cells (VSELs) into cancer stem cells (CSCs) and its role in cancer initiation via epigenetic changes.
Org: Epigeneres Biotech Pvt. Ltd., National Institute for Research in Reproductive and Child Health,
Product
Anticoagulation
Clinical trial
A Prospective Observational Cohort Study of Predictive Factors Related to Prognosis of In-hosiptal Patients With Ischemic Stroke Due to Large-artery Atherosclerosis
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement
Status: Not yet recruiting, Estimated PCD: 2026-05-30
Clinical trial
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves: A Prospective, Randomized, Controlled Non-Inferiority Trial
Status: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Status: Not yet recruiting, Estimated PCD: 2025-09-01